Biotech Values

[DewDiligence]

You’re a little high for two reasons: i) the HIV/HCV co-infected group is not mutually exclusive with the other two groups you cited; and ii) not all HIV patients are reimbursed through the Ryan White program.

The aboven pertains to only the US market, of course. As previously noted, I expect ABBV/ENTA to garner a higher patient share in Europe than in the US.